Aagami gets Contract Extension from US based client developing First-in-Class Non-Opioid Analgesic for Pain Relief

Published : 11 Oct 2021

The month of October brought another contract extension for Aagami. This time from US client developing First-in-Class Non-Opioid Analgesic for Pain Relief. 

 

The client is seeking Investment/Licensing/Co-development/other partnerships. Aagami are supporting them in this endeavor and have opened open numerous discussions in the US, EU and other geographies. This includes an ongoing term sheet level discussion.

 

Aagami also represented the client in BioPharm America 2021 (Sep) and will be representing them again in Bio-Europe 2021 (Oct) and JPM week Jan 2022 including Biotech Showcase.

×
Twitter